Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem

References

• RademakerJHodgkin’s and non-Hodgkin’s lymphomasRadiol Clin North Am200745698317157624
   PubMed Web of Science ®Google Scholar
• ShanklandKRArmitageJOHancockBWNon-Hodgkin lymphomaLancet201238084885722835603
   PubMed Web of Science ®Google Scholar
• HennessyBTHanrahanEODalyPANon-Hodgkin lymphoma: an updateLancet Oncol2004534135315172354
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer Statistics, 2015CA Cancer J Clin20156552925559415
   PubMed Web of Science ®Google Scholar
• WardEDeSantisCRobbinsAChildhood and adolescent cancer statistics, 2014CA Cancer J Clin2014648310324488779
   PubMed Web of Science ®Google Scholar
• KimHParkESLeeSHClinical outcome of relapsed or refractory Burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescentsCancer Res Treat20144635836525043820
   PubMed Web of Science ®Google Scholar
• BhattVRVoseJMHematopoietic stem cell transplantation for non-Hodgkin lymphomaHematol Oncol Clin N Am20142810731095
   PubMed Web of Science ®Google Scholar
• PloskerGLFiggittDPRituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemiaDrugs20036380384312662126
   PubMed Web of Science ®Google Scholar
• HarrisonAMThaljiNMGreenbergAJRituximab for non-Hodgkin’s lymphoma: a story of rapid success in translationClin Transl Sci20147828624528902
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHThe development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsJ Cancer Res Clin Oncol20131391971198423942795
   PubMed Web of Science ®Google Scholar
• ChenRChenBThe role of dasatinib in the management of chronic myeloid leukemiaDrug Des Devel Ther20159773779
   PubMed Web of Science ®Google Scholar
• HatoriMIchinohasamaRMyersJFlow cytometric and genotypic analysis of primary non-Hodgkin’s lymphoma of bonePathol Res Pract19971935575649406249
   PubMedGoogle Scholar
• KuritaDMiuraKNakagawaMDose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphomaInt J Hematol201510158559325776837
   PubMed Web of Science ®Google Scholar
• ChaoMPTreatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Manag Res2013525126924049458
   PubMedGoogle Scholar
• DaridonCBlassfeldDReiterKEpratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusArthritis Res Ther201012R20421050432
   PubMed Web of Science ®Google Scholar
• KatoJO’DonnellRTAbuhayMEfficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphomaOncoimmunology201211469147523264893
   PubMed Web of Science ®Google Scholar
• MorschhauserFKraeber-BodéréFWegenerWAHigh rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin’s lymphomaJ Clin Oncol2010283709371620625137
   PubMed Web of Science ®Google Scholar
• WitzigTETomblynMBMislehJGAnti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaHaematologica2014991738174525150258
   PubMed Web of Science ®Google Scholar
• KurodaSTamJRothJAEGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damageInt J Nanomedicine201493825383925143731
   PubMed Web of Science ®Google Scholar
• WangYYiSSunLCharge-selective fractions of naturally occurring nanoparticles as bioactive nanocarriers for cancer therapyActa Biomater2014104269428424952072
   PubMed Web of Science ®Google Scholar
• WangJChenBChenJSynthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticlesInt J Nanomedicine2011620321121445276
   PubMed Web of Science ®Google Scholar
• WangJChenBChenJApoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles coloaded with daunorubicin and 5-bromotetrandrinInt J Nanomedicine201161027103421720514
   PubMed Web of Science ®Google Scholar
• ChenZZhangYXiaJPreparation and characterization of water-soluble monodispersed magnetic iron nanoparticles via surface double-exchange with DMSAColloids Surf A Physicochem Eng Asp2008316210216
   Web of Science ®Google Scholar
• SohnYSLeeYKSite-directed immobilization of antibody using EDC-NHS-activated protein A on a bimetallic-based surface plasmon resonance chipJ Biomed Opt20141905120924418847
   PubMedGoogle Scholar
• MunnierECohen-JonathanSLinassierCNovel method of doxorubicin-SPION reversible association for magnetic drug targetingInt J Pharm200836317017618687392
   PubMed Web of Science ®Google Scholar
• SadighianSRostamizadehKHosseini-MonfaredHDoxorubicin-conjugated core-shell magnetite nanoparticles as dual-targeting carriers for anticancer drug deliveryColloids Surf B Biointerfaces200411740641324675279
   PubMedGoogle Scholar
• GautierJMunnierEPaillardAA pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targetingInt J Pharm2012423162521703340
   PubMed Web of Science ®Google Scholar
• ReiterASchrappeMTiemannMImproved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90Blood1999943294330610552938
   PubMed Web of Science ®Google Scholar
• OschliesISalaverriaIMahnFPediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma-Berlin-Frankfurt-Münster (NHL-BFM) multicenter trialsHaematologica20109525325919679882
   PubMed Web of Science ®Google Scholar
• PankhurstQAConnollyJJonesSKApplications of magnetic nanoparticles in biomedicineJ Phys D Appl Phys200336R181
   Google Scholar
• QiaoRZengJJiaQMagnetic iron oxide nanoparticle – an important cornerstone of MR molecular imaging of tumorsActa Phys Chim Sin2012289931011
   Web of Science ®Google Scholar
• WuPLiSZhangHDesign real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubesDrug Des Devel Ther2014824312438
   Web of Science ®Google Scholar
• ZajaFTomadiniVZaccariaACHOP-rituximab with PEGylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphomaLeuk Lymphoma2006472174218017071492
   PubMed Web of Science ®Google Scholar
• LuminariSMontaniniAFedericoMAnthracyclines: a cornerstone in the management of non-Hodgkin’s lymphomaHematol Rep201133 Supple422586512
   PubMedGoogle Scholar
• VaupelPTumor microenvironmental physiology and its implications for radiation oncologySemin Radiat Oncol20041419820615254862
   PubMed Web of Science ®Google Scholar
• TannockIFRotinDAcid pH in tumors and its potential for therapeutic exploitationCancer Res198949437343842545340
   PubMed Web of Science ®Google Scholar
• MarinaMLArletteGSBertholdMHow Fe3+ binds anthracycline antitumor compounds. The myth and the reality of a chemical sphinxJ Inorg Biochem19997510511510450605
   PubMed Web of Science ®Google Scholar